Analysis
Analysis
Viking's $575m raise funds its trials, at a price its board should explain
Viking sold $575m of stock and 2% convertible notes after strong maintenance data. The notes were priced in line with peers. The shares went at about 16% below the last close, a deeper discount than comparable raises.
VKTX The raise funds the trials, but the stock was sold cheaply against peers and the board has not explained why.
Analysis: opinion, not investment advice
Viking Therapeutics (VKTX) raised money the day after good news, as bankers advise. On September 22nd it reported that patients who moved from weekly injections of its GLP-1/GIP drug, VK2735, to monthly dosing kept 85% of their weight loss over 12 weeks, against 61% for placebo. The next day it proposed $200m of stock and $200m of convertible notes, and demand let it upsize both. When the deals closed on September 28th, with the underwriters' options exercised in full, Viking had sold 9,035,714 shares at $35 and $258.75m of notes, for gross proceeds of about $575m.
Viking's chief executive is Brian Lian and its chief financial officer is Greg Zante, according to the company's proxy statement, and Lawson Macartney chairs the board. The cash it raised was needed. The price paid for it deserves more scrutiny than it has had.
How long the cash lasts
Viking had $502m in cash and short-term investments at June 30th, down from $706m at the end of 2025. It lost $286.3m in the first half of 2026, and R&D spending in the second quarter alone was $115.8m, almost double a year earlier. Those are the costs of two large injectable phase 3 trials, and since October Viking has also been running an oral phase 3 programme, SUNRISE.
The company put net proceeds at about $297.0m from the shares and $250.8m from the notes. By our arithmetic, adding those to the June balance gives about $1.05bn before third-quarter spending. At the first-half rate of loss, that should carry Viking to its next big readout without a hurried return to the market.
What shareholders paid
The share price is where the board has questions to answer. Viking's stock prospectus gives the last sale price on September 22nd as $40.85, but the deal was priced on September 23rd, after a session in which the shares closed at $41.65. The shares were sold at $35.00, about 16% below that close by our calculation, and the underwriters took $2.10 a share, or 6%. Two weeks later Vaxcyte (PCVX), also raising after a phase 3 win, sold stock at $64.00 against a last sale price of $66.70, a discount of about 4%, and paid underwriting discounts of $26.25m on a $500m deal, or 5.25%. Arcus Biosciences (RCUS), raising in October after kidney cancer data, priced at $17.50 against a last sale of $19.10, about 8% lower, with underwriting discounts of $1.05 a share. Viking's discount was the deepest of the three. The sale was upsized, which suggests demand was strong, so holders may reasonably ask why the price was not set closer to the market.
The convertible looks better. The notes pay 2.00% a year, mature in October 2032 and convert at about $50.75 a share. That is roughly 45% above the $35 offering price and, by our arithmetic, about 22% above the September 23rd close. Underwriters took 3% of the principal, according to the notes prospectus. Halozyme (HALO) sold 1.50% notes due 2033 in September at a 27.5% conversion premium, and Vaxcyte sold 1.50% notes due 2032 in October. A 2% coupon for a company with no product revenue is in that range. Viking may redeem the notes from October 2029 if its stock stays above 130% of the conversion price, and holders can convert early only on specified events.
Even cheap money has a contingent cost. If VK2735 succeeds and the shares climb past $50.75, note holders can take up to about 5.1m shares (19.7044 per $1,000 of principal). If it disappoints, Viking owes $258.75m of senior unsecured debt in 2032, with U.S. Bank Trust Company as trustee, and the notes rank ahead of the shares in a restructuring.
Morgan Stanley and J.P. Morgan were the representatives on both deals. Jefferies, Leerink Partners and William Blair also underwrote the notes, according to the notes prospectus. The stock syndicate was larger: the stock prospectus adds Raymond James, Oppenheimer & Co., Canaccord Genuity, H.C. Wainwright & Co., B. Riley Securities, Maxim Group and Laidlaw & Company (U.K.). Paul Hastings advised Viking and Latham & Watkins advised the underwriters. Together, the underwriting discounts came to roughly $27m by our calculation from the two prospectuses, before Viking's own expenses.
What the money does not settle
Viking has not given a date for results from its injectable VANQUISH phase 3 trials, the readout that matters most. The maintenance study ran for 12 weeks and compared VK2735 with placebo. To win patients, VK2735 will eventually have to beat the approved drugs on convenience, tolerability or price. The second part of the maintenance study will not read out until 2027.
The legal risk gets less attention than it deserves. Viking's third-quarter 10-Q says Ligand Pharmaceuticals (LGND) sued it in San Diego on May 19th, 2026, after Ligand said it was ending Viking's licence to the TR-Beta programme, which includes VK2809 and VK0214. Ligand wants damages and an order making Viking return certain intellectual property. Viking has sued Ligand and its affiliate Metabasis in return, and says it has "good and substantial defenses". A hearing on Ligand's demurrer is set for February 26th, 2027. VK2735 is outside TR-Beta, so the obesity drug is not directly at risk. VK2809 was once Viking's lead asset, though, and anyone putting a value on the rest of the pipeline should mark it down until the court rules.
What the board should explain
J. Matthew Singleton has chaired Viking's audit committee since May 2014 and is its designated financial expert. The company's auditor is CBIZ CPAs. Shareholders at next year's annual meeting would be entitled to ask Mr Singleton, Dr Macartney and Dr Lian three things: why the stock was priced about 16% below its last close before pricing when comparable raises that autumn cost 4% to 8%; how the split between new shares and convertible debt was chosen; and how long the money will last, a figure the 8-K does not give.
What to watch
The third-quarter cash balance and quarterly burn come first: if spending keeps rising, the runway is shorter than the headline figure implies. Then any date for VANQUISH data, which will decide whether the note holders were right to pay up for conversion rights. The Ligand demurrer hearing in February 2027 will give a first read on the licence fight. Last, watch for a partnership. Viking now has about $1bn to negotiate with, and selling an obesity drug takes a sales force it does not have.
Verdict
Viking raised enough to stop financing being the near-term worry, and its convertible was priced in line with the market. The equity was not. Selling stock at a discount twice Arcus's and four times Vaxcyte's cost existing holders money that a firmer negotiation might have saved, and the board has not explained the choice. The raise also leaves open whether VK2735 can take share from much larger rivals and how the dispute over Viking's older drugs ends.
Sources
- kept 85% of their weight loss over 12 weeks, against 61% for placebo
- proposed $200m of stock and $200m of convertible notes
- closed on September 28th
- according to the company's proxy statement
- $502m in cash and short-term investments at June 30th
- oral phase 3 programme, SUNRISE
- about $297.0m from the shares and $250.8m from the notes
- stock prospectus
- closed at $41.65
- last sale price of $66.70
- last sale of $19.10
- notes prospectus
- 1.50% notes due 2033 in September at a 27.5% conversion premium
- 1.50% notes due 2032
- has not given a date
- second part of the maintenance study
- third-quarter 10-Q
Disclosures
- Every figure carries the as-of date of its source.
- This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
- Our method and conflicts policy: aibio.space/disclosures/
As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.
Investor Chat
Loading posts…
aibio